{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 447616853
| image = 
<!-- Clinical data -->
| tradename = Nulojix
| Drugs.com = {{drugs.com|CDI|belatacept}}
| MedlinePlus = a606016
| licence_US = Belatacept
| pregnancy_AU = 
| pregnancy_US = C
| pregnancy_category = 
| legal_AU = 
| legal_CA = 
| legal_UK = 
| legal_US = Rx-only
| legal_status = 
| routes_of_administration = Intravenous
<!-- Pharmacokinetic data -->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 
<!-- Identifiers -->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 
| ATC_prefix = L04
| ATC_suffix = AA28
| PubChem = 
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = 
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = E3B2GI648A
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = none
<!-- Chemical data -->
| chemical_formula = 
| molecular_weight = 
}}

'''Belatacept''' (trade name '''Nulojix''') is a [[fusion protein]] composed of the Fc fragment of a human IgG1 immunoglobulin linked to the extracellular domain of [[CTLA-4]],<ref name="urlctla4igenglish">{{cite web |url=http://www.healthvalue.net/ctlaigenglish.html |title=Healthvalue.net: CTLA-4 Strategies|work= |accessdate=2008-10-24| archiveurl= https://web.archive.org/web/20081205034856/http://www.healthvalue.net/ctlaigenglish.html| archivedate= 5 December 2008 <!--DASHBot-->| deadurl= no}}</ref> which is a molecule crucial in the regulation of T-cell [[costimulation]], selectively blocking the process of T-cell activation. It is intended to provide extended [[Medical grafting|graft]] survival while limiting the toxicity generated by [[immunosuppressive drugs|standard immune suppressing regimen]]s, such as [[calcineurin inhibitor]]s. It differs from [[abatacept]] (Orencia) by only 2 amino acids.

Belatacept was developed by [[Bristol-Myers-Squibb]] and approved by the U.S. [[Food and Drug Administration]] on June 15, 2011.<ref>{{cite press release |url=http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm259184.htm |title=FDA approves Nulojix for kidney transplant patients |publisher=U.S. Food and Drug Administration |date=2011-06-15 |accessdate=2011-06-16| archiveurl= https://web.archive.org/web/20110619051309/http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm259184.htm| archivedate= 19 June 2011 <!--DASHBot-->| deadurl= no}}</ref>

==References==
{{reflist}}

{{Immunosuppressants}}

[[Category:Engineered proteins]]
[[Category:Bristol-Myers Squibb]]


{{antineoplastic-drug-stub}}